Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Mar 14:8:60.
doi: 10.1186/1748-717X-8-60.

Prognostic variables in patients with primary soft tissue sarcoma of the extremity and trunk treated with neoadjuvant radiotherapy or neoadjuvant sequential chemoradiotherapy

Meena Bedi  1 , David M King, Mikesh Shivakoti, Tao Wang, Eduardo V Zambrano, John Charlson, Donald Hackbarth, John Neilson, Robert Whitfield, Dian Wang
Affiliations

Prognostic variables in patients with primary soft tissue sarcoma of the extremity and trunk treated with neoadjuvant radiotherapy or neoadjuvant sequential chemoradiotherapy

Meena Bedi et al. Radiat Oncol. .

Abstract

Background: Neoadjuvant radiotherapy (NRT) is an effective strategy to treat soft tissue sarcomas (STS). However, the role of neoadjuvant chemoradiotherapy (NCRT) remains to be determined.

Methods: From May 1999 to July 2010, 112 patients with localized STS of the extremity and trunk who were treated with NRT or NCRT followed by surgery were retrospectively reviewed. Clinical outcomes including overall survival (OS), disease-free survival (DFS), and distant metastasis free survival (DMFS) were calculated using Kaplan-Meier survival analyses. Prognostic variables were determined by univariate (UVA) and multivariate analyses (MVA).

Results: Median follow-up was 37 months. Median RT dose was 50 Gy. Forty-nine patients received NCRT. Overall limb-preservation rate was 99% and local control was 97%. The estimated 3-year OS, DFS, and DMFS were 86%, 68%, and 72%, respectively. Age was the only variable to predict for OS, DFS and DMFS on UVA. Age ≥ 70 predicted for poor OS, stage III disease predicted for poor DFS and DMFS, and the addition of chemotherapy predicted for improved DMFS on MVA.

Conclusions: Excellent rates of local control and limb-preservation were observed in patients with primary STS treated with neoadjuvant therapy followed by surgery. Neoadjuvant sequential chemotherapy followed by radiotherapy may be considered for young patients with stage III STS.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Overall survival (A), disease-free survival (B), distant metastasis free survival (C) of the entire group.
Figure 2
Figure 2
Distant metastasis free survival (DMFS) of patients with neoadjuvant chemotherapy versus without neoadjuvant chemotherapy.
See this image and copyright information in PMC

References

    1. Bowden L, Booher RJ. The principles and technique of resection of soft parts for sarcoma. Surgery. 1958;44:963–977. - PubMed
    1. Simon MA, Enneking WF. The management of soft-tissue sarcomas of the extremities. J Bone Joint Surg Am. 1976;58:317–327. - PubMed
    1. Rosenberg SA, Tepper J, Glatstein E. The treatment of soft-tissue sarcomas of the extremities: prospective randomized evaluations of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy. Ann Surg. 1982;196:305–315. doi: 10.1097/00000658-198209000-00009. - DOI - PMC - PubMed
    1. O'Sullivan B, Davis AM, Turcotte R. Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial. Lancet. 2002;359:2235–2241. doi: 10.1016/S0140-6736(02)09292-9. - DOI - PubMed
    1. Nielsen OS, Cummings B, O'Sullivan B. Preoperative and postoperative irradiation of soft tissue sarcomas: effect of radiation field size. Int J Radiat Oncol Biol Phys. 1991;21:1595–1599. doi: 10.1016/0360-3016(91)90337-4. - DOI - PubMed